Skip to main content

Dapagliflozin Cuts Cardiovascular Events in Patients With Heart Failure, T2D

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 27, 2023.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Dec. 27, 2023 -- For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27 in eClinicalMedicine.

Fumiki Yoshihara, from the National Cerebral and Cardiovascular Center in Osaka, Japan, and colleagues conducted a multicenter, randomized trial that enrolled patients at 18 medical facilities in Japan to examine the effects of dapagliflozin on UACR in patients with heart failure and T2D. Eligible participants were randomly assigned to a dapagliflozin or control group in a 1:1 ratio (146 and 148 patients, respectively).

At the end of the observation period, 107 patients (87.7 percent) were taking 5 mg dapagliflozin daily. The researchers observed no significant difference in the primary outcome of changes in UACR from baseline after a two-year observation between the dapagliflozin and control groups. Among the secondary end points, the dapagliflozin group had a larger mean decrease in left ventricular end-diastolic dimensions as one of the echocardiographic parameters. Compared with the control group, the dapagliflozin group had the composite end point less often, defined as cardiovascular death or hospitalization for cardiovascular events, hospitalization for heart failure events, hospitalization for all causes, and an additional change in prescriptions for heart failure in a two-year observation.

"The results obtained on the primary end point revealed no significant difference in renal dysfunction judged by UACR between the dapagliflozin and control groups, which is in contrast to previous findings from three randomized controlled trials," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca and Ono Pharmaceuticals, which partially funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Small but Important Differences Seen Between Rosuvastatin, Atorvastatin

WEDNESDAY, Oct. 30, 2024 -- There are small but important differences in risk for some clinical outcomes associated with rosuvastatin and atorvastatin, according to a study...

AI Can Help ID Patients With Diabetes at Highest Risk for Cardiomyopathy

WEDNESDAY, Oct. 30, 2024 -- Machine learning can help identify individuals with diabetes at high risk for diabetic cardiomyopathy (DbCM), according to a study published online...

Eucaloric Carbohydrate-Restricted Diet Improves β-Cell Function in T2DM

FRIDAY, Oct. 25, 2024 -- A eucaloric carbohydrate-restricted (CR) diet improves β-cell response to glucose in patients with type 2 diabetes (T2D), according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.